All Updates

All Updates

icon
Filter
Funding
Partnerships
ElevateBio raises USD 401 million in Series D; LifeEdit partners with Novo Nordisk
Human Gene Editing
May 24, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Human Gene Editing

Human Gene Editing

May 24, 2023

ElevateBio raises USD 401 million in Series D; LifeEdit partners with Novo Nordisk

Funding
Partnerships

  • Massachusetts-based gene editing biotechnology company ElevateBio has raised USD 401 million in a Series D funding round led by the AyurMaya Capital Management Fund and managed by Matrix Capital Management. The round also saw participation from new investors Woodline, Lee Family Office (Asia), and Novo Nordisk, and existing investors Matrix Capital Management and The Invus Group, among others. This round marks the largest fundraising in 2023 thus far.

  • The proceeds will be directed toward further developing the company’s gene editing technologies, including the LifeEdit platform, and its centralized R&D and manufacturing company, BaseCamp. The funds will also support ElevateBio’s expansion plans geographically, as well as the capacity expansion of its current Good Manufacturing Practice (cGMP) manufacturing capacity to be able to offer turnkey solutions to partners.

  • Concurrently, ElevateBio’s subsidiary, LifeEdit, entered a multi-target collaboration with Novo Nordisk, one of the Series D investors, to discover and develop novel base editing treatments across seven programs. LifeEdit will receive an upfront payment, as well as milestone payments of USD 250 million to USD 335 million for each of the seven programs. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.